Back

Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM

29 August 2026 (16:30 - 16:45)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Fernando Dominguez

Hospital Universitario Puerta De Hierro Majadahonda, Madrid (Spain)

3 More presentations in this session

Presentation thumbnail
Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial
Doctor S. Hegde (Dallas, US)
Slides Video
Presentation thumbnail
Deep Learning Model for Detection, Phenotyping, and Left Ventricular Gradient Estimation in Hypertrophic Cardiomyopathy Using Echocardiography: Development and Multinational External Validation
Doctor F. Alenezi (Durham, US)
Slides Video
Presentation thumbnail
Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE
Doctor A. Owens (Philadelphia, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: hypertrophic cardiomyopathy
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Dose-dependent effects of aficamten vs metoprolol in MAPLE-HCM
11 May 2026
thumbnail
Congress Presentation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
31 August 2025
thumbnail
Congress Presentation
Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy
30 August 2025
thumbnail
Congress Presentation
Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources